Literature DB >> 12651994

Comorbid illness in women with chronic fatigue syndrome: a test of the single syndrome hypothesis.

Donald S Ciccone1, Benjamin H Natelson.   

Abstract

OBJECTIVE: Evidence of comorbidity among unexplained illness syndromes raises the possibility that all are variants of a single functional disorder, leading some to suggest that separate case definitions for chronic fatigue syndrome (CFS), fibromyalgia (FM), and multiple chemical sensitivity (MCS) may be unnecessary. Our objective was to determine whether discrete diagnostic labels provide useful information about physical functioning, symptom severity, and risk of psychiatric illness.
METHODS: The sample consisted of 163 consecutive female referrals with CFS enrolled at a tertiary clinic. Each participant was retrospectively assigned to one of four groups: CFS only, CFS/FM, CFS/MCS, and CFS/FM/MCS. At enrollment, participants gave their history, underwent a physical examination and a standardized psychiatric interview (Diagnostic Interview Schedule), and answered self-report questionnaires.
RESULTS: Additional unexplained syndromes were prevalent: 37% met criteria for FM, and 33% met criteria for MCS. With the exception of FM-related pain and disability, there were few differences between the CFS only and CFS with comorbid illness groups. Patients with additional illness were more likely to have major depression and a higher risk of psychiatric morbidity compared with patients in the CFS only group (p <.01). Rates of lifetime depression increased from 27.4% in the CFS only group to 52.3% in the CFS/FM group, 45.2% in the CFS/MCS group, and 69.2% in the CFS/FM/MCS group.
CONCLUSIONS: The prevalence of comorbid illness in the present CFS sample and the failure to find widespread differences in symptom severity can be seen as support for the single syndrome hypothesis. On the other hand, the existence of discrete syndromes could not be ruled out because of reliable differences between CFS and CFS/FM. Increasing comorbidity was associated with a corresponding increase in risk of major depression.

Entities:  

Mesh:

Year:  2003        PMID: 12651994     DOI: 10.1097/01.psy.0000033125.08272.a9

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  35 in total

1.  Chemical intolerance in primary care settings: prevalence, comorbidity, and outcomes.

Authors:  David A Katerndahl; Iris R Bell; Raymond F Palmer; Claudia S Miller
Journal:  Ann Fam Med       Date:  2012 Jul-Aug       Impact factor: 5.166

2.  A population-based twin study of functional somatic syndromes.

Authors:  K Kato; P F Sullivan; B Evengård; N L Pedersen
Journal:  Psychol Med       Date:  2008-06-26       Impact factor: 7.723

3.  Cytokines across the night in chronic fatigue syndrome with and without fibromyalgia.

Authors:  Toru Nakamura; Stephan K Schwander; Robert Donnelly; Felix Ortega; Fumiharu Togo; Gordon Broderick; Yoshiharu Yamamoto; Neil S Cherniack; David Rapoport; Benjamin H Natelson
Journal:  Clin Vaccine Immunol       Date:  2010-02-24

4.  Neurocognitive complaints and functional status among patients with chronic fatigue syndrome and fibromyalgia.

Authors:  Karen B Schmaling; Karran L Betterton
Journal:  Qual Life Res       Date:  2015-10-15       Impact factor: 4.147

5.  Gene expression alterations at baseline and following moderate exercise in patients with Chronic Fatigue Syndrome and Fibromyalgia Syndrome.

Authors:  A R Light; L Bateman; D Jo; R W Hughen; T A Vanhaitsma; A T White; K C Light
Journal:  J Intern Med       Date:  2011-07-13       Impact factor: 8.989

6.  Sex differences in plasma prolactin response to tryptophan in chronic fatigue syndrome patients with and without comorbid fibromyalgia.

Authors:  Shelley A Weaver; Malvin N Janal; Nadine Aktan; John E Ottenweller; Benjamin H Natelson
Journal:  J Womens Health (Larchmt)       Date:  2010-05       Impact factor: 2.681

7.  Health-related quality of life in patients with chronic fatigue syndrome: group cognitive behavioural therapy and graded exercise versus usual treatment. A randomised controlled trial with 1 year of follow-up.

Authors:  Montserrat Núñez; Joaquim Fernández-Solà; Esther Nuñez; José-Manuel Fernández-Huerta; Teresa Godás-Sieso; Esther Gomez-Gil
Journal:  Clin Rheumatol       Date:  2011-01-15       Impact factor: 2.980

8.  The effect of comorbid medical and psychiatric diagnoses on chronic fatigue syndrome.

Authors:  Benjamin H Natelson; Jin-Mann S Lin; Gudrun Lange; Sarah Khan; Aaron Stegner; Elizabeth R Unger
Journal:  Ann Med       Date:  2019-11-07       Impact factor: 4.709

9.  Children's Somatization Inventory: psychometric properties of the revised form (CSI-24).

Authors:  Lynn S Walker; Joy E Beck; Judy Garber; Warren Lambert
Journal:  J Pediatr Psychol       Date:  2008-09-09

10.  Effect of Milnacipran Treatment on Ventricular Lactate in Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Benjamin H Natelson; Diana Vu; Xiangling Mao; Nora Weiduschat; Fumiharu Togo; Gudrun Lange; Michelle Blate; Guoxin Kang; Jeremy D Coplan; Dikoma C Shungu
Journal:  J Pain       Date:  2015-08-31       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.